The life sciences industry has kept up with an accelerated pace of venture investment in past years. What is venture capital and what role does it play in early stage life sciences companies? How do investors evaluate biopharmaceutical and medical devices companies before making investment decisions? What are the key considerations driving an investment decision? How do venture capital investors add value to their portfolio companies? What are some of the current trends within life sciences venture investing?

Speaker’s Biography

Dr. Carolyn Ng is Vice President of Vertex Ventures HC, the venture capital arm of Temasek Holdings specializing in early stage life sciences investments globally. At Vertex, Dr. Ng is responsible for evaluating and driving venture investments across health tech, biotechnology, and medical device fields. Oncology scientist by background, Dr. Ng is passionate about innovation that impacts patients’ lives. Dr. Ng works closely with entrepreneurs, community leaders, life science corporations, and government bodies in shaping a strong and vibrant healthcare startup ecosystem in Singapore. Prior to joining Vertex, Dr. Ng was a Strategy Consultant at Deallus Consulting, a specialized London-headquartered life sciences consulting firm with clientele comprised of the top 20 global pharmaceutical companies.

Dr. Ng holds a PhD in Cancer Molecular Biology from the NUS Graduate School for Integrative Sciences and Technology (NGS), where she was a recipient of the prestigious NGS PhD Scholarship. During her academic career, she was the co-inventor of a novel small molecule nuclear receptor activator indicated for the treatment of neuroblastoma. She also holds a BS (Pharmacy) (First Class Honours) degree from the National University of Singapore.

Venue: Duke-NUS Medical School, Meeting Room 7C, Level 7